Neuroendocrine tumors are generally slow growing and are frequently discovered when metastatic spread has occurred. This leaves room for multiple treatments, individualized through a multidisciplinary approach that considers tumor type, extension, and related symptoms. In almost 15 years of academic phase II trials, PRRT with either 90Y-octreotide or 177Lu-octreotate proved to be efficient, with tumor responses in more than 30% of patients, symptom relief and QoL improvement, biomarker reduction, and, ultimately, an impact on survival.